Müller-Gärtner H W, Wilson A A, Dannals R F, Wagner H N, Frost J J
Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
J Cereb Blood Flow Metab. 1992 Jul;12(4):562-70. doi: 10.1038/jcbfm.1992.80.
A method to image muscarinic acetylcholine receptors (muscarinic receptors) noninvasively in human brain in vivo was developed using [123I]4-iododexetimide ([123I]IDex), [123I]4-iodolevetimide ([123I]ILev), and single photon emission computed tomography (SPECT). [123I]IDex is a high-affinity muscarinic receptor antagonist. [123I]ILev is its pharmacologically inactive enantiomer and measures nonspecific binding of [123I]IDex in vitro. Regional brain activity after tracer injection was measured in four young normal volunteers for 24 h. Regional [123I]IDex and [123I]ILev activities were correlated early after injection, but not after 1.5 h. [123I]IDex activity increased over 7-12 h in neocortex, neostriatum, and thalamus, but decreased immediately after the injection peak in cerebellum. [123I]IDex activity was highest in neostriatum, followed in rank order by neocortex, thalamus, and cerebellum. [123I]IDex activity correlated with muscarinic receptor concentrations in matching brain regions. In contrast, [123I]ILev activity decreased immediately after the injection peak in all brain regions and did not correspond to muscarinic receptor concentrations. [123I]IDex activity in neocortex and neostriatum during equilibrium was six to seven times higher than [123I]ILev activity. The data demonstrate that [123I]IDex binds specifically to muscarinic receptors in vivo, whereas [123I]ILev represents the nonspecific part of [123I]IDex binding. Subtraction of [123I]ILev from [123I]IDex images on a pixel-by-pixel basis therefore reflects specific [123I]IDex binding to muscarinic receptors. Owing to its high specific binding, [123I]IDex has the potential to measure small changes in muscarinic receptor characteristics in vivo with SPECT. The use of stereoisomerism directly to measure nonspecific binding of [123I]IDex in vivo may reduce complexity in modeling approaches to muscarinic acetylcholine receptors in human brain.
利用[123I]4-碘右旋美托咪定([123I]IDex)、[123I]4-碘左旋美托咪定([123I]ILev)和单光子发射计算机断层扫描(SPECT),开发了一种在人体大脑中对毒蕈碱型乙酰胆碱受体(毒蕈碱受体)进行无创成像的方法。[123I]IDex是一种高亲和力的毒蕈碱受体拮抗剂。[123I]ILev是其药理学上无活性的对映体,用于在体外测量[123I]IDex的非特异性结合。在4名年轻正常志愿者中,测量了示踪剂注射后24小时的脑区活性。注射后早期,脑区[123I]IDex和[123I]ILev活性相关,但在1.5小时后不相关。[123I]IDex活性在新皮质、新纹状体和丘脑中在7 - 12小时内增加,但在小脑注射峰值后立即下降。[123I]IDex活性在新纹状体中最高,其次依次为新皮质、丘脑和小脑。[123I]IDex活性与匹配脑区中的毒蕈碱受体浓度相关。相比之下,[123I]ILev活性在所有脑区注射峰值后立即下降,且与毒蕈碱受体浓度不对应。平衡期新皮质和新纹状体中的[123I]IDex活性比[123I]ILev活性高6至7倍。数据表明,[123I]IDex在体内特异性结合毒蕈碱受体,而[123I]ILev代表[123I]IDex结合的非特异性部分。因此,逐像素地从[1·23I]IDex图像中减去[123I]ILev反映了[123I]IDex与毒蕈碱受体的特异性结合。由于其高特异性结合,[123I]IDex有潜力利用SPECT测量体内毒蕈碱受体特征的微小变化。直接利用立体异构现象测量[123I]IDex在体内的非特异性结合可能会降低人脑中毒蕈碱型乙酰胆碱受体建模方法的复杂性。